Skip to content
Clinical Trials – home

Hospital Vall d’Hebron

Verified siteinfo

Spain Passeig De La Vall D'Hebron 119-129, 08035 Barcelona, Spain

  • 802 trials recruiting
  • Non-small cell lung cancer · Neoplasm · Neoplasm malignant
  • Adults and children

About Specializations

Hospital Vall d’Hebron in Barcelona, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Neoplasm, Neoplasm malignant, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases at Hospital Vall d’Hebron

Research here focuses on pulmonary arterial hypertension, a serious condition affecting the blood vessels in the lungs. The trials are designed to explore whether targeted supportive treatment can improve symptoms, functional capacity, and risk status while helping prevent clinical worsening.

  • Studying pulmonary arterial hypertension in patients with idiopathic, hereditary, drug- and toxin-induced, and connective tissue disease-associated forms
  • Evaluating vitamin D supplementation as a potential way to improve clinical outcomes and reduce worsening of disease

This work reflects a strong interest in better managing cardiopulmonary complications through more effective supportive care and outcome monitoring.

Immune System Diseases

The Lupus Unit at Vall d’Hebron Institut de Recerca is conducting research in systemic lupus erythematosus, especially severe and treatment-resistant cases. These studies aim to assess new therapeutic options for improving disease control and safety in people with difficult-to-manage autoimmune disease.

  • Investigating severe, refractory systemic lupus erythematosus in patients who need better treatment options
  • Testing a new cell-based therapy to evaluate early signs of benefit and tolerability

The research highlights ongoing efforts to advance care for complex autoimmune diseases by finding approaches that may offer meaningful improvement where standard treatments are not enough.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Passeig De La Vall D'Hebron 119-12908035 BarcelonaSpain
Recruiting now
802 trials
Conditions studied
685
Partner status
Verified site

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 085 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:HLX43
  • Sponsor:Shanghai Henlius Biotech Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.